Cannabinoid Biosciences is a biopharmaceutical company that intends to research, develop, and commercialize treatments derived from cannabinoids. It plans to raise $125 million through private placements to fund the acquisition of 10 profitable cannabis dispensaries and cultivation facilities which it will consolidate and take public on a major stock exchange, aiming to provide investors exposure to the ground floor of the cannabis industry. The company projects the rollup could be worth over $4.6 billion once public based on industry multiples.
GET IN ON THE GROUND FLOOR OF CANNABIS INVESTMENT
WITH CBDZ SECURED CONVERTIBLE 8% NOTES
Cannabinoid Biosciences Inc. (CBDZ) is the first-female controlled Cannabis IPO in the United States and Canada.
CBDZ is offering a Secured Convertible Note paying 12% annual interest.
A $1,000 Note is convertible into 80 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share.
The minimum investment is $1,000 per unit of our Secured 8% Convertible Notes offered under Reg. D 506 (c).
CBDZ has agreed to buy 10 dispensaries with $54 million in annual revenue from their current owners for $49 million. The consolidation rollup would do IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE).
Once CBDZ successfully listed on the NASDAQ, a $1,000 investment could fetch a lot more because NASDAQ and NYSE market-participants pay $131 - $215 for $1 of sale for rollup/consolidated Cannabis business.
If Real Estate is a Stable passive income investment and Medical Marijuana is THE Fastest growing Industry. Why not combine both and create 420 Capital Holding
Cannabinoid Biosciences Inc. (CBDZ) is the first female controlled Cannabis IPO in the United States and Canada. This is a Secured Convertible Note paying 12% annual interest. A $1,000 Note is convertible into 125 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share. The minimum investment is $1,000 per unit of our Secured Convertible Notes offered under Reg. D 506 (c). CBDZ has agreed to buy 10 dispensaries from their current owners for $49 million. The 10 dispensaries has $54 million in annual revenue. With the purchase, rollup and consolidation of the 10 dispensaries, CBDZ will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE). Once CBDZ successfully listed on the NASDAQ, that $1,000 investment could fetch up to $21,500 based on what the NASDAQ and NYSE market-participants pay for rollup/consolidated Cannabis business. These market-participants pay an average of $131 per $1 of revenue for Cannabis businesses.
Opportunity to get in on the ground floor of cannabis investment, with a Secured 12% Convertible Notes. Company is set for a 2019 NASDAQ IPO through Regulation A+ which has already been filed with the SEC.
GET IN ON THE GROUND FLOOR OF CANNABIS INVESTMENT
WITH CBDZ SECURED CONVERTIBLE 8% NOTES
Cannabinoid Biosciences Inc. (CBDZ) is the first-female controlled Cannabis IPO in the United States and Canada.
CBDZ is offering a Secured Convertible Note paying 12% annual interest.
A $1,000 Note is convertible into 80 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share.
The minimum investment is $1,000 per unit of our Secured 8% Convertible Notes offered under Reg. D 506 (c).
CBDZ has agreed to buy 10 dispensaries with $54 million in annual revenue from their current owners for $49 million. The consolidation rollup would do IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE).
Once CBDZ successfully listed on the NASDAQ, a $1,000 investment could fetch a lot more because NASDAQ and NYSE market-participants pay $131 - $215 for $1 of sale for rollup/consolidated Cannabis business.
If Real Estate is a Stable passive income investment and Medical Marijuana is THE Fastest growing Industry. Why not combine both and create 420 Capital Holding
Cannabinoid Biosciences Inc. (CBDZ) is the first female controlled Cannabis IPO in the United States and Canada. This is a Secured Convertible Note paying 12% annual interest. A $1,000 Note is convertible into 125 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share. The minimum investment is $1,000 per unit of our Secured Convertible Notes offered under Reg. D 506 (c). CBDZ has agreed to buy 10 dispensaries from their current owners for $49 million. The 10 dispensaries has $54 million in annual revenue. With the purchase, rollup and consolidation of the 10 dispensaries, CBDZ will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE). Once CBDZ successfully listed on the NASDAQ, that $1,000 investment could fetch up to $21,500 based on what the NASDAQ and NYSE market-participants pay for rollup/consolidated Cannabis business. These market-participants pay an average of $131 per $1 of revenue for Cannabis businesses.
Opportunity to get in on the ground floor of cannabis investment, with a Secured 12% Convertible Notes. Company is set for a 2019 NASDAQ IPO through Regulation A+ which has already been filed with the SEC.
Level Brands (NYSE American: LEVB) is an innovative brand management and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. Level Brands owns and operates the nationally recognized consumer cannabidiol (CBD) brand cbdMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils, and CBD pet products. The Company's primary licensing and corporate brand management businesses target consumer products in the health and wellness space and other high-demand verticals, bringing innovative products to market under the kathy ireland® Health & Wellness; Ireland Men One (I'M1), and Encore Endeavor One (EE1) brands. Learn more at www.LEVBinfo.com.
Level Brands, Inc. (NYSE American: LEVB), an innovative brand management and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. Level Brands owns and operates the nationally recognized consumer cannabidiol (CBD) brand cbdMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils, and CBD pet products. The Company's primary licensing and corporate brand management businesses target consumer products in the health and wellness space and other high-demand verticals, bringing innovative products to market under the kathyireland® Health & Wellness; Ireland Men One (I'M1), and Encore Endeavor One (EE1) brands.
Commerce Resources Corp. (TSXv: CCE; FSE: D7H) is pleased to announce that it has filed an amended and restated final short form prospectus, amending and restating the short form prospectus dated February 25, 2016, with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units (the “Units”) of the Company at a reduced price of $0.075 per Unit for gross proceeds of a minimum of $1 million and up to a maximum of $3 million.
Crop is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The company's portfolio of projects includes cultivation properties in California, Washington State, Nevada, Italy, Jamaica, and a joint venture on West Hollywood and San Bernardino dispensary applications. Crop has developed a portfolio of 15 cannabis brands and has U.S. and Italian distribution rights to a line of over 55 topical cannabis products from The Yield Growth Corp.
A Securities and Exchange Commission filing that shows hedge fund Hirzel Capital Management has purchased nearly 5 million shares of Rex Energy stock--9% of total outstanding shares. Since it is a Form 13G it indicates this is a "passive" investment.
Commerce Resources Corp. (TSXv: CCE; FSE: D7H) is pleased to announce that it has filed on February 26, 2016, a final short form prospectus with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units (the “Units”) of the Company at a price of $0.10 per Unit for gross proceeds of a minimum of $1 million and up to a maximum of $3 million (the “Offering”). The Company has granted the agent an over-allotment option to sell up to an additional 15% of the Offering on the same terms and conditions, exercisable at any time following the closing of the Offering for a period of 30 days.
Better Choice Company (OTCQB: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. Better Choice takes an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings, and positions its portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. The Company has a demonstrated, multi-decade track record of success selling trusted animal health and wellness products, and leverage its established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. Better Choice sells the majority of its dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats.
Opportunity to get in on the ground floor of cannabis investment. Company plans late 2019 NASDAQ IPO via Reg. A+. A $1,000 invested at the ground floor would equal to paying $2 for $1 of sales, and would be worth a lot more post-IPO, in twelve months because the post-IPO NASDAQ and NYSE pay $131-$215 for $1 of sales for Cannabis rollup/consolidated.
Cannabinoid Biosciences Inc. (CBDZ) is the first-female controlled Cannabis IPO in the United States and Canada. This is a Secured Convertible Note paying 12% annual interest. A $1,000 Note is convertible into 125 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share.
Level Brands (NYSE American: LEVB) is an innovative brand management and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. Level Brands owns and operates the nationally recognized consumer cannabidiol (CBD) brand cbdMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils, and CBD pet products. The Company's primary licensing and corporate brand management businesses target consumer products in the health and wellness space and other high-demand verticals, bringing innovative products to market under the kathy ireland® Health & Wellness; Ireland Men One (I'M1), and Encore Endeavor One (EE1) brands. Learn more at www.LEVBinfo.com.
Level Brands, Inc. (NYSE American: LEVB), an innovative brand management and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. Level Brands owns and operates the nationally recognized consumer cannabidiol (CBD) brand cbdMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils, and CBD pet products. The Company's primary licensing and corporate brand management businesses target consumer products in the health and wellness space and other high-demand verticals, bringing innovative products to market under the kathyireland® Health & Wellness; Ireland Men One (I'M1), and Encore Endeavor One (EE1) brands.
Commerce Resources Corp. (TSXv: CCE; FSE: D7H) is pleased to announce that it has filed an amended and restated final short form prospectus, amending and restating the short form prospectus dated February 25, 2016, with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units (the “Units”) of the Company at a reduced price of $0.075 per Unit for gross proceeds of a minimum of $1 million and up to a maximum of $3 million.
Crop is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The company's portfolio of projects includes cultivation properties in California, Washington State, Nevada, Italy, Jamaica, and a joint venture on West Hollywood and San Bernardino dispensary applications. Crop has developed a portfolio of 15 cannabis brands and has U.S. and Italian distribution rights to a line of over 55 topical cannabis products from The Yield Growth Corp.
A Securities and Exchange Commission filing that shows hedge fund Hirzel Capital Management has purchased nearly 5 million shares of Rex Energy stock--9% of total outstanding shares. Since it is a Form 13G it indicates this is a "passive" investment.
Commerce Resources Corp. (TSXv: CCE; FSE: D7H) is pleased to announce that it has filed on February 26, 2016, a final short form prospectus with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units (the “Units”) of the Company at a price of $0.10 per Unit for gross proceeds of a minimum of $1 million and up to a maximum of $3 million (the “Offering”). The Company has granted the agent an over-allotment option to sell up to an additional 15% of the Offering on the same terms and conditions, exercisable at any time following the closing of the Offering for a period of 30 days.
Better Choice Company (OTCQB: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. Better Choice takes an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings, and positions its portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. The Company has a demonstrated, multi-decade track record of success selling trusted animal health and wellness products, and leverage its established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. Better Choice sells the majority of its dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats.
Opportunity to get in on the ground floor of cannabis investment. Company plans late 2019 NASDAQ IPO via Reg. A+. A $1,000 invested at the ground floor would equal to paying $2 for $1 of sales, and would be worth a lot more post-IPO, in twelve months because the post-IPO NASDAQ and NYSE pay $131-$215 for $1 of sales for Cannabis rollup/consolidated.
Cannabinoid Biosciences Inc. (CBDZ) is the first-female controlled Cannabis IPO in the United States and Canada. This is a Secured Convertible Note paying 12% annual interest. A $1,000 Note is convertible into 125 shares of CBDZ Common Stock which is currently being registered with the SEC under Reg. A+, to be sold at $10 per share.
Raising Private Equity Capital for Expansion, Insurance and Business Mergers/...Cannabis Legal Group
Raising Private Equity Capital for Expansion, Insurance and Business Mergers/Acquisitions by Erik Allison, Managing Partner at Skytree Capital Partners
New 2024 CBD Products Manufacturing Investor Pitch Deck TemplateCannaBusinessPlans
We offer a '70% ready to go' professional CBD Products Manufacturing Investor Pitch Deck Template for PowerPoint. The template is completely open and editable, and all you have to do is add your company information. https://hempcbdbusinessplans.com/product/investor-pitch-deck-template-hemp-cbd-manufacturing-business/
CBIO Brand Development Inc. is a Vancouver, Canada based HempDerived CBD product company whose manufacturing partner uses a
revolutionary patented pharmaceutical grade ingredient as the base
for all its formulations, for people and their pets. CBIO is currently
commercializing several ailment specific brands for immediate
release into the U.S. wholesale market.
Hemp CBD Vertically Integrated Business Pitch Deck will help you to prepare your presentation to potential investors, because raising money from investors for your growing startup is challenging at any stage and requires a great pitch.
https://hempcbdbusinessplans.com/product/investor-pitch-deck-template-hemp-cbd-vertically-integrated-business/
Investor presentation for Flower One Holdings, updated for Q2 2020. The Company's common shares are traded on the Canadian Securities Exchange under the Company's symbol "FONE", in the United States on the OTCQX Best Market under the symbol "FLOOF" and on the Frankfurt Stock Exchange under the symbol "F11". For more information, visit: https://flowerone.com.
A complete cannabis business plan package is everything you need to create a 100% legally compliant professional business plan for cannabis retail business with expert financials and projections.
https://cannabusinessplans.com/product/cannabis-dispensary-business-plan-template-profit/
New 2024 Cannabis Microbusiness Business Plan Template, Type 12CannaBusinessPlans
Requirements for microbusiness licenses vary from place to place. For example, the Type 12 license in California is for businesses that do at least three of the following activities at one location: cultivation, manufacturing, distribution (or distribution transport-only), retail (storefront or non-storefront). An adult-use microbusiness in New York must engage in cannabis cultivation and at least one additional licensed activity including processing, distribution, or retail sale. This template includes cultivation and nursery, processing and manufacturing, retail with or without delivery or non-storefront. It works for vertically integrated cannabis business operations however it is flexible enough to be used for only some of them or even for a mono business. https://cannabusinessplans.com/product/cannabis-microbusiness-business-plan-template/
Medical Marijuana Sales Hit $1 Billion in MarylandCannabis News
Maryland has a big medical marijuana market, read this https://cannabis.net/blog/news/maryland-medical-marijuana-sales-hit-1-billion-in-less-than-40-months-new-billion-in-sales-pred
Using industry-leading standards, equipment, and techniques, Desert Cannalytix will provide clients with a full suite of cannabis testing services including compliance testing, research and development testing, quality assurance, dosage measurements, and labeling.
Investor presentation for Flower One Holdings following their announcement of Q1 2020 results. The Company's common shares are traded on the Canadian Securities Exchange under the Company's symbol "FONE", in the United States on the OTCQX Best Market under the symbol "FLOOF" and on the Frankfurt Stock Exchange under the symbol "F11". For more information, visit: https://flowerone.com.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...rowala30
Alka magic plan 1350 -we deliver alkaline water at your door step and you can make handsome money by referral programme
we also help and provide systematic guideline to setup 1000 lph alkaline water plant
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
1. A California Based
Biopharmaceutical
Company
Www.CBDXFUND.COM
This Cannabinoid Biosciences presentation contains
certain forward-looking statements that are subject to
known and unknown risks and uncertainties that
could cause actual results to differ materially from
those expressed or implied by such statements.
Such risks and uncertainties include, but are not
limited to the Risk Factors noted in the Company’s
filings with the Securities and Exchange Commission.
The Company undertakes no obligations to update
any forward-looking statements, whether as a result
of new information, future events or otherwise.
2. About Us
Company Introduction
Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical
company, which intends to engage in the discovery, development and
commercialization of cures and novel therapeutics derived from:
• Proprietary Cannabinoid
• Cannabidiol, Endocannabinoids
• Phytocannabinoids
• Synthetic Cannabinoids product platform suitable for specific
treatments in a broad range of disease areas.
Www.CBDXFUND.COM
3. 3
Biopharmaceutical R&D and
commercialization of cures
and novel therapeutics from
cannabinoids product
formulations for broad
range of disease areas.
RESEARCH & DEVELOPMENT
Our Business
Details about our business
INVESTMENTS & CONSOLIDATION
Investments into legal-
cannabis businesses and
deriving value from
rollup/consolidation events
that leads to IPO in US or
Canada
FINANCIAL PRODUCTS
Financial products in form of
asset-backed loans, business
property mortgages and other
financial products to qualified
individuals/businesses in the
legal-cannabis businesses
Services include top-level financial
reporting, Accounting, SEC Reporting,
Business Valuation, Mergers &
Acquisitions, GAAP/ IFRS Conversion,
IPO/RTO Prep, Section 280E Tax, and
Biological Assets Valuation to legal-
cannabis businesses.
PROFESSIONAL SERVICES
Www.CBDXFUND.COM
4. 4
Our Market
Market Opportunity
As of November 30, 2018, Thirty-three states and the District
of Columbia currently have passed laws and/or regulations
that recognize, in one form or another, legitimate medical
uses for cannabis and consumer use of cannabis in
connection with medical treatment.
• The District of Columbia and 10 states -- Alaska, California,
Colorado, Maine, Massachusetts, Michigan, Nevada,
Oregon, Vermont and Washington -- have adopted the
most expansive laws legalizing marijuana for recreational
use.
• It is no wonder then that the legal marijuana market in the
U.S. is estimated to grow from $9.2 billion in 2017 to $47.3
billion in 2027.
• Another report from RBC Capital Markets showed that
American cannabis sales are quickly catching up to those
of beer and wine, and the market could be worth $47 billion
within a decade.
Www.CBDXFUND.COM
5. 5
Regulation
Cannabis Regulations
The regulatory environment is gradually shifting more
favorably on medical cannabis biopharmaceutical
cannabinoid at both federal and state level.
• For example, the H.R. 2, the Agriculture Improvement
Act of 2018, also known as the 2018 Farm Bill, H.R. 2
includes a provision that lift the ban on hemp,
authorize hemp production and research and amend
the Controlled Substances Act. See.
https://rules.house.gov/bill/115/hr-2.
• On December 12, 2018, U.S. Congress approved a
Bill to Make CBD Federally Legal. Passage of 2018
Farm Bill clarifies CBD legal status and lets U.S.
farmers grow hemp, but some regulatory questions
remain.
Www.CBDXFUND.COM
6. 6
Competition
Competition in Cannabis Industry
Right now there is no fund focused on rollup of existing high-
margin dispensaries California and across the U.S.
marketplace. In California for example, with 358 licensed
recreational marijuana stores, the state’s three licensing
authorities have issued over 5,000 commercial cannabis
licenses. So competition is not an issue now.
• There is excitement in the air as market sentiment among
investors and companies alike in the legal marijuana industry
grows more positive. Many states are promising to deliver new
markets, reducing risk exposure from the federal government
legally intervening. This situation is creating an inviting
paradigm for investors; stabilized business environments,
breakthroughs in Congress, and shifts in federal enforcement.
• Cannabis-related business such as our research and
development of cannabinoid, cannabidiol, endocannabinoids,
phytocannabinoids, and synthetic cannabinoids product
platform suitable for specific treatments, are gaining
acceptance in the eyes of the general public including the
recent pronouncements and conducts of the U.S. Food and
Drug Administration (FDA), showed that federal authorities are
not opposed to such research and development. Www.CBDXFUND.COM
7. 7
Opportunities For Cannabinoid Biosciences, Inc.
CBDZ is offering a Secured Convertible Note paying 8% annual interest. A
$1,000 Note is convertible into 80 shares of CBDZ Common Stock which is
currently being registered with the SEC under Reg. A+, to be sold at $10 per
share. CBDZ want to raise $125 million with Regulation A+ ($50 million) and
Regulation D 506(c) ($75 million).
• CBDZ is offering ordinary investors a quantified opportunity to get in at the ground floor of
Cannabis investment, at $2 for $1 of revenue.
• CBDZ will rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the
NASDAQ or NYSE and Canadian Securities Exchange (CSE). Once CBDZ successfully listed on
the NASDAQ, the $1,000 investment could would equal to paying $2 for $1 of sales, and would be
worth a lot more post-IPO because the post-IPO NASDAQ and NYSE pay $131-$215 for $1.
• The average Cannabis business trading on the market is selling at about $131-$215 times
revenue. This market cap to revenue only included those Cannabis businesses that have
revenue, since many of those currently trading have little or no revenue.
• Having worked on the rollups and consolidations that led to those public offering, we believe that
we could package a rollup that would provide investors with a chance to enter the cannabis
industry at the ground floor. For example, buying dispensaries and cultivation facilities at 2 time
revenue.
Our Potential
OPPORTUNITY TO GET IN ON THE GROUND FLOOR OF CANNABIS INVESTMENT
Www.CBDXFUND.COM
8. 8
Rollup & Consolidation
Investment Opportunity
Two of our business units are in flux and have
investment opportunities that we want to capitalize
upon immediately.
CBDZ want to raise $125 million with Regulation A+
($50 million), which is waiting for SEC qualification;
and Regulation D 506(c) ($75 million) through which
CBDZ is offering a Secured Convertible Note paying
8% annual interest with a minimum amount of $1,000
per unit.
* Each A $1,000 Note is convertible into 80 shares of
CBDZ Common Stock which is currently being
registered with the SEC under Reg. A+, to be sold at
$10 per share.
* Rollup and Consolidation: Investments into legal-
cannabis businesses and deriving value from
rollup/consolidation events that leads to IPO in US or
Canada; and
* Financial products in form of asset-backed loans,
business property mortgages and other financial
products to qualified individuals/businesses in the
legal-cannabis businesses.
Www.CBDXFUND.COM
9. 9
Rollup & Consolidation
Investment Opportunity
We need to raise $75 million to acquire ≥10 dispensaries which
we’ll rollup into our holding company and IPO on the NASDAQ or
New York Stock Exchange. All our targeted acquisitions are
profitable operations. We plan to keep 50% of the profits for
future growth, and pay 50% back to our investors as dividends.
CBDZ provide investors with opportunity to invest in the
cannabis industry at the ground floor. For example, if an investor
wants to invest in the publicly traded cannabis businesses on the
stock market today, the investor would be paying $131-$215 for
every $1.00 of revenue on average.
Investing with us would give the investors a better deal because
we’ll be acquiring cannabis businesses at close to 2:1 investment to
revenue. For example, with the 10 dispensaries identified, we’ll be
buying at less than $2.00 for every $1.00 of revenue.
We project that this rollup could be worth $4.6 billion on
the stock exchange once we have finished rollup and
consolidation of all the 10 dispensaries and cultivation
facilities. This valuation is based on the weighted average
multiple of X-sales and X-net profit of cannabis
businesses currently trading on the exchanges. Www.CBDXFUND.COM
10. 10
Cannabinoid Biosciences Market Opportunity
CBDZ has identified and
negotiated to purchase 10
dispensaries with cultivation
licenses in a multi-state rollup
that would be consolidated and
IPOed on the major exchanges in
Canada and the United States.
CBDZ has already filed a Reg A+
prospectus with the SEC for a
$50 million raise. We need to
raise $75 million via Regulation D
506 (c) via crowdfunding for the
acquisition.
Check out the chart below to see
why CBDZ actually offers
investors a quantified opportunity
to get in at the ground floor of
Cannabis investment, at $2 for
$1 of revenue.
Www.CBDXFUND.COM
12. 12
5 Year Pro-Forma Summary
Compared to the currently NASDAQ/NYSE listed peers of ACB, CANN, CBDZ,
CGC, CRON, APHA and GWPH, a $54 million revenue with robust profitability
of $17 million would give CBDZ a market valuation north of $7.1 billion and
south of $2.2 billion.
2019 2020 2021 2022 2023
Revenue
Retail and Wholesales 54,237,238 63,544,375 74,448,621 87,224,040 102,191,728
Real Estate and Financial 372,320 1,703,880 3,420,480 4,593,480 5,383,480
Industry Turnkey Solutions 294,000 3,243,600 13,149,321 17,318,186 22,068,824
Compliance Solutions 56,000 1,329,000 4,212,000 5,122,000 7,642,000
Industry Rollup 0 0 0 60,000,000
Total Gross Revenue (USD) 54,959,558 69,820,855 95,230,422 114,257,706 197,286,032
Net profit $17,091,402 $20,024,295 $23,460,474 $27,486,303 $32,202,966
Dividend Distributions 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Reinvestments 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Projected Market Capitalization $4.68 Billion $5.48 Billion $6.42 Billion $7.52 Billion $8.82 Billion
Visit us at: Www.CBDXFUND.COM
13. The following summarizes the key
terms of the Secured Convertible
Notes and the private placement.
Please refer to the relevant
sections of the PPM and related
documents, including the
Company‛s articles of
incorporation (“Articles”) for
more complete details about the
Secured Convertible Notes and the
private placement.
Visit us at: Www.CBDXFUND.COM
14. Issuer Cannabinoid Biosciences, Inc.
Security Secured Convertible Note into Common Stock
Discount 0%
Interest Rate 8% Per Annum (payable fifteen days after the end of the year)
Maturity December 31st 2023
Valuation Cap N/A
Floor N/A
Minimum Subscription $1,000 per investor
Maximum Subscription $75 million per investor
Initial Closing Min. of $10K before 03/07/2020
Additional Closings One or more; up to a total of $75 million
Use of Proceeds Rollup Cannabis and fund growth across US
Dividend Declarations Dividend payment in year 4, subject to Board approval
Liquidity Event Sale of company or listing on a major stock exchange
Mandatory Conversion Converts to Shares of Common Stock
Resale Restrictions No resale permitted within 12 months & Board approval
Voting Rights Per Cannabinoid Biosciences Inc. Articles of Incorporation and By Laws
Registrar and Transfer Agent FundAmerica (VStock Transfer)
Escrow Company Prime Trust
Corporate Bank Bank of America
Legal Counsel Law Office of Azuka L Uzoh
ISIN / CUSIP To be issued
Governing Law Laws of California Visit us at: Www.CBDXFUND.COM
15. A California Based
Biopharmaceutical
company
Thank You
Www.CBDXFUND.COM
Frank I Igwealor, CPA, JD, MBA, CMA, CFM, MSRM
Sr. Vice President and CFO
This Cannabinoid Biosciences presentation contains
certain forward-looking statements that are subject to
known and unknown risks and uncertainties that
could cause actual results to differ materially from
those expressed or implied by such statements.
Such risks and uncertainties include, but are not
limited to the Risk Factors noted in the Company’s
filings with the Securities and Exchange Commission.
The Company undertakes no obligations to update
any forward-looking statements, whether as a result
of new information, future events or otherwise.